Peran vitamin D pada multipel sklerosis

https://doi.org/10.22146/bns.v21i1.109474

Chikita Medika Putri(1*), Cempaka Thursina Srie Setyaningrum(2), Ahmad Asmedi(3)

(1) Gadjah Mada University
(2) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta/RSUP Dr Sardjito
(3) Departemen Neurologi Fakultas Kedokteran, Kesehatan Masyarakat, dan Keperawatan, Universitas Gadjah Mada, Yogyakarta/RSUP Dr Sardjito
(*) Corresponding Author

Abstract


Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system marked by immune-mediated inflammation and demyelination that can lead to permanent disability, influenced by both genetic and environmental factors. Diagnosis is established using the updated 2024 McDonald criteria. Currently, there is no cure for MS. It remains a major cause of non-traumatic disability in young adults and is associated with a reduced life expectancy of 7–14 years. Treatments of MS include relapse treatment, symptom control, and disease-modifying therapies (DMTs). Vitamin D has emerged as an important immunomodulatory factor that may influence MS susceptibility, disease activity, and progression. Its deficiency is linked to a higher risk of developing MS. This review evaluates recent evidence on the immunological actions of vitamin D and its potential as adjunct therapy. Literature searches through PubMed, Scopus, and Cochrane (2016–2025) identified clinical studies and systematic reviews indicating that supplementation may lower inflammatory biomarkers and modestly reduce disease activity, although clinical benefits and optimal dosing remain uncertain. Overall, vitamin D plays a meaningful role in MS pathophysiology and shows therapeutic promise, warranting further investigation.

 

ABSTRAK

Multipel sklerosis (MS) adalah penyakit autoimun kronis sistem saraf pusat yang diperantarai imunitas, inflamasi, dan demielinasi yang menyebabkan disabilitas permanen, serta dipengaruhi faktor genetik dan lingkungan. Diagnosis ditegakkan berdasarkan gambaran klinis termasuk riwayat dan temuan pemeriksaan menggunakan kriteria McDonald terbaru tahun 2024. Saat ini belum ada obat yang dapat menyembuhkan MS. Penyakit ini menjadi penyebab utama disabilitas non-traumatik pada dewasa muda dengan pengurangan harapan hidup 7 hingga 14 tahun. Pengobatan MS terdiri dari pengobatan eksaserbasi/kekambuhan, penatalaksanaan gejala, dan disease-modifying therapies (DMT). Vitamin D mendapat perhatian sebagai faktor imunomodulator yang berpotensi memengaruhi kerentanan, aktivitas, dan progresivitas MS. Defisiensi vitamin D dikaitkan dengan meningkatnya kejadian MS. Tinjauan pustaka ini bertujuan menganalisis bukti ilmiah terbaru mengenai mekanisme vitamin D dalam regulasi imun, serta potensi suplementasi vitamin D sebagai terapi tambahan pada MS. Pencarian literatur dilakukan melalui PubMed, Scopus, dan Cochrane selama 10 tahun terakhir (2016-2025), mencakup studi klinis dan tinjauan sistematis. Hasil pencarian menunjukkan bahwa suplementasi vitamin D dapat menurunkan biomarka inflamasi dan berpotensi mengurangi aktivitas penyakit, meskipun efektivitas klinis dan dosis optimal belum sepenuhnya konsisten. Vitamin D berperan penting dalam patofisiologi MS dan menjanjikan sebagai terapi adjuvan, namun dibutuhkan penelitian lanjutan.


Keywords


vitamin D; multiple sclerosis; DMT



References

Goldschmidt C, McGinley MP. Advances in the Treatment of Multiple Sclerosis. Neurologic Clinics. 2021 Feb;39(1):21–33.

Feige J, Moser T, Bieler L, Schwenker K, Hauer L, Sellner J. Vitamin D Supplementation in Multiple Sclerosis: A Critical Analysis of Potentials and Threats. Nutrients. 2020 Mar 16;12(3):783.

Talanki Manjunatha R, Habib S, Sangaraju SL, Yepez D, Grandes XA. Multiple Sclerosis: Therapeutic Strategies on the Horizon. Cureus. 2022 May 10;14(5).

Dankers W, Colin EM, van Hamburg JP, Lubberts E. Vitamin D in Autoimmunity: Molecular Mechanisms and Therapeutic Potential. Frontiers in Immunology [Internet]. 2017 Jan 20;7(697).

Sintzel MB, Rametta M, Reder AT. Vitamin D and Multiple Sclerosis: A Comprehensive Review. Neurology and Therapy [Internet]. 2017 Dec 14;7(1):59–85.

Haki M, AL-Biati HA, Al-Tameemi ZS, Ali IS, Al-hussaniy HA. Review of multiple sclerosis: Epidemiology, etiology, pathophysiology, and treatment. Medicine [Internet]. 2024 Feb 23;103(8):e37297–7.

Klineova S, Lublin FD. Clinical Course of Multiple Sclerosis. Cold Spring Harbor Perspectives in Medicine. 2018 Jan 22;8(9):a028928.

Dighriri IM, Aldalbahi AA, Albeladi F, Tahiri AA, Kinani EM, Almohsen RA, et al. An Overview of the History, Pathophysiology, and Pharmacological Interventions of Multiple Sclerosis. Cureus [Internet]. 2023 Jan 2;15(1).

Ghasemi N, Razavi S, Nikzad E. Multiple sclerosis: Pathogenesis, symptoms, diagnoses and cell-based therapy. Cell Journal [Internet]. 2017 Dec 21;19(1):1–10.

Montalban X, Lebrun-Frenay C, Oh J, Arrambide G, Moccia M, Amato MP, et al. Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria. Lancet Neurol. 2025 Oct;24(10):850-865.

Tafti D, Ehsan M, Xixis KL. Multiple Sclerosis [Internet]. PubMed. Treasure Island (FL): StatPearls Publishing; 2024. Available from: https://www.ncbi.nlm.nih.gov/books/NBK499849/

Baskaran AB, Grebenciucova E, Shoemaker T, Graham EL. Current Updates on the Diagnosis and Management of Multiple Sclerosis for the General Neurologist. Journal of Clinical Neurology (Seoul, Korea) [Internet]. 2023 May 1;19(3):217–29.

Gonzalez-Lorenzo M, Ridley B, Minozzi S, Cinzia Del Giovane, Peryer G, Piggott T, et al. Immunomodulators and immunosuppressants for relapsing-remitting multiple sclerosis: a network meta-analysis. The Cochrane library [Internet]. 2024 Jan 4;2024(1).

Srivastava SB. Vitamin D: Do We Need More Than Sunshine? American Journal of Lifestyle Medicine. 2021 Apr 3;15(4):155982762110056.

Khammissa RAG, Fourie J, Motswaledi MH, Ballyram R, Lemmer J, Feller L. The Biological Activities of Vitamin D and Its Receptor in Relation to Calcium and Bone Homeostasis, Cancer, Immune and Cardiovascular Systems, Skin Biology, and Oral Health. BioMed Research International [Internet]. 2018;2018:1–9.

Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. Reviews in endocrine & metabolic disorders [Internet]. 2017;18(2):153–65.

Fatima M, Lamis A, Siddiqui SW, Ashok T, Patni N, Fadiora OE. Therapeutic Role of Vitamin D in Multiple Sclerosis: An Essentially Contested Concept. Cureus. 2022 Jun 22;14(6):e26186.

Khosravi-Largani M, Pourvali-Talatappeh P, Rousta AM, Karimi-Kivi M, Noroozi E, Mahjoob A, et al. A review on potential roles of vitamins in incidence, progression, and improvement of multiple sclerosis. eNeurologicalSci. 2018 Mar;10:37–44.

Harrison SR, Li D, Jeffery LE, Raza K, Hewison M. Vitamin D, Autoimmune Disease and Rheumatoid Arthritis. Calcified Tissue International [Internet]. 2019 Jul 8;106(1):58–75.

Sparaco M, Bonavita S. Vitamin D Supplementation: Effect on Cytokine Profile in Multiple Sclerosis. Journal of Clinical Medicine. 2024 Feb 1;13(3):835–5.

Hashemi R, Morshedi M, Asghari Jafarabadi M, Altafi D, Saeed Hosseini-Asl S, Rafie-Arefhosseini S. Anti-inflammatory effects of dietary vitamin D3 in patients with multiple sclerosis. Neurology: Genetics [Internet]. 2018 Nov 14;4(6).

Galoppin M, Kari S, Soldati S, Pal A, Rival M, Engelhardt B, et al. Full spectrum of vitamin D immunomodulation in multiple sclerosis: mechanisms and therapeutic implications. Brain Communications. 2022 Jun 30;4(4).

Mrad MF, El K, Esmerian MO, Kazan JM, Khoury SJ. Effect of vitamin D replacement on immunological biomarkers in patients with multiple sclerosis. Clinical Immunology. 2017 May 20;181:9–15.
Smolders J, Torkildsen Ø, Camu W, Holmøy T. An Update on Vitamin D and Disease Activity in Multiple Sclerosis. CNS Drugs. 2019 Nov 4;33(12):1187–99.

Hupperts R, Smolders J, Vieth R, Holmøy T, Marhardt K, Schluep M, et al. Randomized trial of daily high-dose vitamin D3 in patients with RRMS receiving subcutaneous interferon β-1a. Neurology. 2019 Oct 8;93(20):e1906-e1916.

Camu W, Lehert P, Pierrot-Deseilligny C, Hautecoeur P, Besserve A, Jean Deleglise AS, et al. Cholecalciferol in relapsing-remitting MS: A randomized clinical trial (CHOLINE). Neurology - Neuroimmunology Neuroinflammation [Internet]. 2019 Aug 6;6(5):e597.

Cassard SD, Fitzgerald KC, Qian P, Emrich SA, Azevedo CJ, Goodman AD, et al. High-dose vitamin D3 supplementation in relapsing-remitting multiple sclerosis: a randomised clinical trial. EClinicalMedicine. 2023 Apr 13;59:101957.

Mahler JV, Solti M, Apóstolos-Pereira SL, Adoni T, Silva GD, Callegaro D. Vitamin D3 as an add-on treatment for multiple sclerosis: A systematic review and meta-analysis of randomized controlled trials. Mult Scler Relat Disord. 2024 Feb;82:105433.

Butzkueven H, Ponsonby AL, Stein MS, Lucas RM, Mason D, Broadley S, et al. Vitamin D did not reduce multiple sclerosis disease activity after a clinically isolated syndrome. Brain. 2024 Apr 4;147(4):1206-1215.

Thouvenot E, Laplaud D, Lebrun-Frenay C, Derache N, Le Page E, Maillart E, et al. High-Dose Vitamin D in Clinically Isolated Syndrome Typical of Multiple Sclerosis: The D-Lay MS Randomized Clinical Trial. JAMA. 2025 Apr 22;333(16):1413-1422.

Wakeman M. A Literature Review of the Potential Impact of Medication on Vitamin D Status. Risk Manag Healthc Policy. 2021 Aug 14;14:3357-3381.

Galus W, Walawska-Hrycek A, Rzepka M, Krzystanek E. Vitamin D Supplementation Practices among Multiple Sclerosis Patients and Professionals. Journal of Clinical Medicine [Internet]. 2022 Dec 8;11(24):7278.

Tebben PJ, Singh RJ, Kumar R. Vitamin D-Mediated Hypercalcemia: Mechanisms, Diagnosis, and Treatment. Endocrine Reviews [Internet]. 2016 Oct;37(5):521–47.
Ramasamy I. Vitamin D Metabolism and Guidelines for Vitamin D Supplementation. Clinical Biochemist Reviews. 2020 Dec 8;41(3):103–26.

Tobias DK, Luttman-Gibson H, Mora S, Danik J, Bubes V, Copeland T, et al. Association of Body Weight With Response to Vitamin D Suppplementation and Metabolism. 2023;6(1):e2250681.



DOI: https://doi.org/10.22146/bns.v21i1.109474

Article Metrics

Abstract views : 70 | views : 23

Refbacks

  • There are currently no refbacks.


Copyright (c) 2026 Berkala NeuroSains

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.